These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 20589847)
41. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes. Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340 [TBL] [Abstract][Full Text] [Related]
42. A computational approach to tuning the photochemistry of platinum(IV) anticancer agents. Tai HC; Zhao Y; Farrer NJ; Anastasi AE; Clarkson G; Sadler PJ; Deeth RJ Chemistry; 2012 Aug; 18(34):10630-42. PubMed ID: 22807241 [TBL] [Abstract][Full Text] [Related]
43. Possible biotransformation reactions of polynuclear Pt(II) complexes. Summa N; Maigut J; Puchta R; van Eldik R Inorg Chem; 2007 Mar; 46(6):2094-104. PubMed ID: 17311374 [TBL] [Abstract][Full Text] [Related]
44. Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding. Kasparkova J; Vrana O; Farrell N; Brabec V J Inorg Biochem; 2004 Oct; 98(10):1560-9. PubMed ID: 15458817 [TBL] [Abstract][Full Text] [Related]
45. Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro. Kratochwil NA; Zabel M; Range KJ; Bednarski PJ J Med Chem; 1996 Jun; 39(13):2499-507. PubMed ID: 8691447 [TBL] [Abstract][Full Text] [Related]
46. The new antitumor compound, cis-[Pt(NH3)2(4-methylpyridine)Cl]Cl, does not form N7,N7-d(GpG) chelates with DNA. An unexpected preference for platinum binding at the 5'G in d(GpG). Lempers EL; Bloemink MJ; Brouwer J; Kidani Y; Reedijk J J Inorg Biochem; 1990 Sep; 40(1):23-35. PubMed ID: 2283508 [TBL] [Abstract][Full Text] [Related]
47. Probing platinum azido complexes by 14N and 15N NMR spectroscopy. Farrer NJ; Gierth P; Sadler PJ Chemistry; 2011 Oct; 17(43):12059-66. PubMed ID: 21922574 [TBL] [Abstract][Full Text] [Related]
48. Use of top-down and bottom-up Fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs. Li H; Lin TY; Van Orden SL; Zhao Y; Barrow MP; Pizarro AM; Qi Y; Sadler PJ; O'Connor PB Anal Chem; 2011 Dec; 83(24):9507-15. PubMed ID: 22032417 [TBL] [Abstract][Full Text] [Related]
49. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899 [TBL] [Abstract][Full Text] [Related]
50. DNA interstrand cross-links of an antitumor trinuclear platinum(II) complex: thermodynamic analysis and chemical probing. Malina J; Farrell NP; Brabec V Chem Asian J; 2011 Jun; 6(6):1566-74. PubMed ID: 21557487 [TBL] [Abstract][Full Text] [Related]
51. Dinuclear platinum complexes with biological relevance based on the 1,2-diaminocyclohexane carrier ligand. Williams JW; Qu Y; Bulluss GH; Alvorado E; Farrell NP Inorg Chem; 2007 Jul; 46(15):5820-2. PubMed ID: 17592835 [TBL] [Abstract][Full Text] [Related]
52. Structural Factors Affecting Binding of Platinum Anticancer Agents with Phospholipids: Influence of Charge and Phosphate Clamp Formation. Gorle AK; Zhang J; Liu Q; Berners-Price SJ; Farrell NP Chemistry; 2018 Mar; 24(18):4643-4652. PubMed ID: 29341369 [TBL] [Abstract][Full Text] [Related]